Marina Konopleva

Marina Konopleva

UNVERIFIED PROFILE

Are you Marina Konopleva?   Register this Author

Register author
Marina Konopleva

Marina Konopleva

Publications by authors named "Marina Konopleva"

Are you Marina Konopleva?   Register this Author

100Publications

2622Reads

36Profile Views

Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.

Blood 2019 Oct;134(15):1257-1268

Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019002457DOI Listing
October 2019

Three-Dimensional Leukemia Co-Culture System for In Vitro High-Content Metabolomics Screening.

SLAS Discov 2019 Sep 25;24(8):817-828. Epub 2019 Jul 25.

1 Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2472555219860446DOI Listing
September 2019

Amino acid metabolism in hematologic malignancies and the era of targeted therapy.

Blood 2019 Sep 15;134(13):1014-1023. Epub 2019 Aug 15.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019001034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764269PMC
September 2019

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.

Ther Adv Hematol 2019 23;10:2040620719874733. Epub 2019 Sep 23.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719874733DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759709PMC
September 2019

A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs.

Cell Death Dis 2019 Aug 13;10(8):617. Epub 2019 Aug 13.

Department of BioSciences, Rice University, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1851-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692368PMC
August 2019

Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis.

Catheter Cardiovasc Interv 2019 Aug 13. Epub 2019 Aug 13.

Keele Cardiovascular Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Keele, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccd.28432DOI Listing
August 2019

Refining statistics clarifies leukaemic stem cell genomics.

Br J Haematol 2019 Jun 26;185(5):1005-1007. Epub 2018 Nov 26.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15697DOI Listing
June 2019

Photoacoustic-based oxygen saturation assessment of murine femoral bone marrow in a preclinical model of leukemia.

Photoacoustics 2019 Jun 20;14:31-36. Epub 2019 Feb 20.

Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pacs.2019.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484208PMC
June 2019

Venetoclax-based therapies for acute myeloid leukemia.

Best Pract Res Clin Haematol 2019 06 24;32(2):145-153. Epub 2019 May 24.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581210PMC
June 2019

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Leuk Lymphoma 2019 Jun 27:1-4. Epub 2019 Jun 27.

b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1633635DOI Listing
June 2019

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

N Engl J Med 2019 05;380(22):2095-2103

From the Departments of Leukemia (N.J., M. Keating, P.T., A.F., J.B., G.B., K.T., Z.E., T.K., M. Konopleva, Y.A., M.Y., C.D., P.B., M.O., N.P., E.J., K. Sasaki, K. Sondermann, N.C., C.W., A.A., H.K., W.W.), Lymphoma and Myeloma (N.F.), Hematopathology (R.K.-S., K.P., J.J.), Diagnostic Radiology (N.G.), Biostatistics (X.W.), and Experimental Therapeutics (W.P., V.G.), University of Texas M.D. Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1900574DOI Listing
May 2019

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

N Engl J Med 2019 04;380(17):1628-1637

From the University of Texas M.D. Anderson Cancer Center, Houston (N.P., M.D., H.M.K., M.K.); Dana-Farber Cancer Institute (A.A.L.) and Boston University School of Medicine (J.M.S.), Boston, and Veristat, Southborough (J.B.) - all in Massachusetts; H. Lee Moffitt Cancer Center, Tampa, FL (K.L.S., J.E.L.); City of Hope National Medical Center, Duarte, CA (A.S.S.); Ohio State University, Columbus (S.V.); Winship Cancer Institute of Emory University, Atlanta (W.B.); Duke University Medical Center, Durham, NC (D.A.R.); and Roswell Park Comprehensive Cancer Center, Buffalo (E.S.W.), and Stemline Therapeutics, New York (S. Spence, S. Shemesh, C.L.B., I.B.) - both in New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815105DOI Listing
April 2019

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.

N Engl J Med 2019 02;380(7):695-6

Dana–Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1814963DOI Listing
February 2019

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy.

Oncotarget 2019 Feb 8;10(12):1250-1265. Epub 2019 Feb 8.

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383813PMC
February 2019

Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer.

Metabolites 2019 Jan 9;9(1). Epub 2019 Jan 9.

Department of Bioinformatics and Computational Biology and The Proteomics and Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/metabo9010010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359345PMC
January 2019

BCL-2 inhibition in AML: an unexpected bonus?

Blood 2018 09 23;132(10):1007-1012. Epub 2018 Jul 23.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-03-828269DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235069PMC
September 2018

Targeting dihydroorotate dehydrogenase in acute myeloid leukemia.

Haematologica 2018 09;103(9):1415-1417

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.197806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119147PMC
September 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

J Clin Oncol 2018 06 27;36(18):1788-1797. Epub 2018 Apr 27.

Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P. Patel, P. Andrew Futreal, and Koichi Takahash, The University of Texas MD Anderson Cancer Center, Houston, TX; Kiyomi Morita, The University of Tokyo, Tokyo; and Koichi Takahashi, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008108PMC
June 2018

Leukemia Stem Cells Microenvironment.

Adv Exp Med Biol 2017 ;1041:19-32

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-69194-7_3DOI Listing
May 2018

ORY-1001: Overcoming the Differentiation Block in AML.

Cancer Cell 2018 03;33(3):342-343

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.02.014DOI Listing
March 2018

mTOR inhibition enhances efficacy of dasatinib in -rearranged Ph-like B-ALL.

Oncotarget 2018 Jan 6;9(5):6562-6571. Epub 2018 Jan 6.

Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814232PMC
January 2018

T-PLL: another check on the venetoclax list?

Blood 2017 12;130(23):2447-2448

UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-10-809673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721286PMC
December 2017

Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.

Cancer Cell 2017 Dec;32(6):748-760.e6

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.11.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730338PMC
December 2017

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

Expert Rev Hematol 2017 10 21;10(10):863-874. Epub 2017 Aug 21.

a Department of Leukemia , University of Texas, MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1366852DOI Listing
October 2017

Tumor status and genotype affect the bone marrow microenvironment in acute myeloid leukemia.

Oncotarget 2017 Oct 6;8(48):83354-83369. Epub 2017 Jul 6.

Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.19042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663521PMC
October 2017

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.

Cancers (Basel) 2017 Sep 10;9(9). Epub 2017 Sep 10.

Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers9090121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615336PMC
September 2017